title: Poor benefit/risk balance of intravenous immunoglobulins in DRESS.
authors.forename: Pascal
authors.initials: P
authors.lastname: Joly
authors.forename: Baptiste
authors.initials: B
authors.lastname: Janela
authors.forename: Florence
authors.initials: F
authors.lastname: Tetart
authors.forename: Sylvie
authors.initials: S
authors.lastname: Rogez
authors.forename: Damien
authors.initials: D
authors.lastname: Picard
authors.forename: Michel
authors.initials: M
authors.lastname: D'Incan
authors.forename: Vincent
authors.initials: V
authors.lastname: Descamps
authors.forename: Evelyne
authors.initials: E
authors.lastname: Collet
authors.forename: Jean Claude
authors.initials: JC
authors.lastname: Roujeau
authors.forename: Philippe
authors.initials: P
authors.lastname: Musette
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003587:Cytomegalovirus / Q000502:physiology; D018450:Disease Progression; D003875:Drug Eruptions / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D005260:Female; D005334:Fever / Q000209:etiology; D004854:Herpesvirus 4, Human / Q000502:physiology; D015654:Herpesvirus 6, Human / Q000502:physiology; D016199:Herpesvirus 7, Human / Q000502:physiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D007371:Interferon-gamma / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D018570:Risk Assessment; D048069:Tumor Necrosis Factors / Q000097:blood; D014775:Virus Activation
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D048069:Tumor Necrosis Factors; D007371:Interferon-gamma